Valuation: Replimune Group, Inc.

Market Cap 1.39B 1.19B 1.11B 1.02B 1.92B 133B 1.94B 13.15B 5.11B 66.64B 5.2B 5.09B 220B P/E 2027 *
-5.18x
P/E 2028 * -6.3x
Enterprise Value 1.31B 1.12B 1.05B 959M 1.81B 125B 1.83B 12.42B 4.83B 62.94B 4.91B 4.81B 208B EV / Sales 2027 *
29.6x
EV / Sales 2028 * 6.78x
Free-Float
98.3%
Yield 2027 *
-
Yield 2028 * -
1 day-0.41%
1 week+0.55%
Current month+31.34%
1 month+51.65%
3 months+199.59%
6 months+75.96%
Current year+51.34%
1 week 13.81
Extreme 13.81
15.64
1 month 4.76
Extreme 4.7648
15.7
Current year 1.5
Extreme 1.5
15.7
1 year 1.5
Extreme 1.5
15.7
3 years 1.5
Extreme 1.5
21.32
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 2024-03-31
Director of Finance/CFO 46 2023-09-18
Chief Tech/Sci/R&D Officer 60 2022-11-30
Director TitleAgeSince
Chairman 54 2024-03-31
Director/Board Member 66 2017-06-30
Chairman 65 2020-03-31
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Chief Financial Officer

-9,256 0.0119%
8/11/26
Baker Bros. Advisors LP
BuyCompany 2,736,340 3.5056%
8/10/26 Sell

Controller/Auditor

-7,632 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+0.55%+159.44%-27.93% 1.39B
-0.74%+3.78%+3.74%+23.10% 51.21B
+1.01%-0.20%+471.68%+564.93% 45.35B
+0.16%+7.88%+36.14%+20.76% 42.84B
-0.66%+2.61%+18.59%+87.04% 42.29B
+0.88%-3.48%+17.20%+53.83% 32.15B
-0.12%+3.84%+33.73%+145.25% 17.31B
-0.53%+1.84% - - 16.55B
+0.58%+4.66%+7.17%+30.87% 14.84B
+1.15%+4.17%+84.49%+50.33% 14.25B
Average +0.13%+2.96%+92.47%+105.35% 27.82B
Weighted average by Cap. +0.10%+3.06%+101.61%+140.48%

Financials

2027 *2028 *
Net sales 44.29M 37.96M 35.51M 32.47M 61.27M 4.24B 61.92M 420M 163M 2.13B 166M 163M 7.05B 193M 166M 155M 142M 267M 18.5B 270M 1.83B 713M 9.29B 725M 710M 30.73B
Net income -291M -249M -233M -213M -402M -27.82B -406M -2.76B -1.07B -13.97B -1.09B -1.07B -46.22B -234M -200M -187M -171M -323M -22.37B -327M -2.22B -862M -11.23B -877M -858M -37.17B
Net Debt -77M -65.99M -61.73M -56.44M -107M -7.37B -108M -730M -284M -3.7B -289M -283M -12.25B -77M -65.99M -61.73M -56.44M -107M -7.37B -108M -730M -284M -3.7B -289M -283M -12.25B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
26-08-24 US$14.71 -0.41% 2,081,184
26-08-21 US$14.77 +5.12% 2,969,475
26-08-20 US$14.05 -5.13% 4,295,922
26-08-19 US$14.81 -4.94% 3,441,404
26-08-18 US$15.58 +6.49% 2,245,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.71USD
Average target price
19.33USD
Spread / Average Target
+31.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock